AstraZeneca Pharma India Analyst Review 2027: Sales Jump 30% but Profit Lags and P/E Stays Near 86
- November 20, 2026
- Posted by: Chaitanya Auti
- Category: Market
AstraZeneca Pharma India Stock Snapshot (19 Nov 2026)
- Current Market Price (CMP): ₹6,113
- 52-Week High / Low: ₹9,264 / ₹5,640
- Market Capitalisation: ₹15,300 crore
- P/E Ratio vs Industry P/E: 86 vs 51.5
- Latest Quarter (Q2 FY27) Revenue: ₹729.10 crore
- Latest Quarter (Q2 FY27) Net Profit: ₹62.33 crore
Quick Answer: The AstraZeneca Pharma India analyst review 2027 finds no fresh named brokerage target as of November 2026, so results and valuation are the main guide. Q2 FY27 revenue from operations rose 30.4% to ₹729.10 crore, while net profit grew 15% to ₹62.33 crore. The stock closed at ₹6,113 on 19 November 2026, about 34% below its 52-week high, at roughly 86 times trailing earnings, which frames any AstraZeneca Pharma India share price target 2027 discussion.
The AstraZeneca Pharma India analyst review 2027 looks at the Indian listed arm of the global drug maker AstraZeneca, which sells medicines for cancer, diabetes, heart, kidney, lung and rare diseases. Readers searching for an AstraZeneca Pharma India share price target 2027 want to know whether strong sales growth can support a premium valuation after a sharp fall from the highs.
AstraZeneca Pharma India closed at ₹6,113 on 19 November 2026, about 34% below its 52-week high of ₹9,264 and only about 8% above its low of ₹5,640. This AstraZeneca Pharma India analyst review 2027 explains what drove the September quarter and what shapes the AstraZeneca Pharma India stock outlook 2027.
Click Here – Get Free Investment Predictions
What Analysts Say in the AstraZeneca Pharma India Analyst Review 2027
| Brokerage | Rating | Target Price | Date |
|---|---|---|---|
| No fresh named coverage found | Not available | Not available | As of November 2026 |
We could not verify any named brokerage report with a target price on AstraZeneca Pharma India after the Q2 FY27 results. The free float is small because the parent holds 75%, and that limits institutional research interest.
Without published targets, this AstraZeneca Pharma India analyst review 2027 leans on reported numbers, the product pipeline and the valuation gap with the wider pharma sector.
Q2 FY27 Results in the AstraZeneca Pharma India Analyst Review 2027
| Metric | Q2 FY27 | Q2 FY26 | Change |
|---|---|---|---|
| Revenue from operations | ₹729.10 crore | ₹559.09 crore | Up 30.4% |
| Profit before exceptional items and tax | ₹103.45 crore | ₹78.11 crore | Up 32.4% |
| Net profit | ₹62.33 crore | ₹54.22 crore | Up 15.0% |
| EPS | ₹24.93 | ₹21.69 | Up 14.9% |
| Q1 FY27 revenue | ₹682.79 crore | Not applicable | Up 6.8% QoQ |
Sales grew strongly across key therapy areas, and the rare disease business was a standout. Industry reports said rare disease revenue rose to about ₹204 crore in Q2 from about ₹38 crore a year earlier, which added a large share of the quarter’s growth.
Net profit grew about half as fast as revenue, because the operating margin stayed near 13%. In this AstraZeneca Pharma India analyst review 2027, the gap between sales growth and profit growth is the main question for investors paying a high multiple.
The quarter also improved sharply on Q1 FY27, when net profit was about ₹37.9 crore. That sequential jump suggests the cost base can absorb growth, though one quarter does not set a trend.
How AstraZeneca Pharma India Makes Money
AstraZeneca Pharma India imports and markets the parent group’s patented and branded medicines in India.
- Oncology: targeted cancer drugs, which carry high prices and long patent lives.
- Cardiovascular, renal and metabolism: diabetes, heart failure and kidney disease treatments.
- Respiratory: inhaled therapies for asthma and lung conditions.
- Rare diseases: specialised therapies from the group’s rare disease unit, now growing fast in India.
FY26 marked a strong year of sales growth, and the first half of FY27 has continued that pace with revenue of about ₹1,412 crore. That momentum is the base of this AstraZeneca Pharma India analyst review 2027.
The model is asset light. The company relies on global research and imported products, so it spends little on plants, but its margins depend on transfer prices paid to the parent and on currency moves. A weaker rupee raises the cost of imported medicines.
Return on equity is about 20%, and debt to equity of about 0.11 is low. The company pays a small dividend, with a yield near 0.6% at the current price.
Investors comparing pharma names often look at the Nifty Pharma index, where generic exporters dominate. AstraZeneca Pharma India is different, because it sells patented innovator drugs only in the domestic market, so it is less exposed to US pricing pressure but more exposed to Indian price controls.
Growth Triggers in the AstraZeneca Pharma India Analyst Review 2027
- Revenue momentum: sales up about 30% in both Q1 and Q2 FY27.
- Rare disease ramp up: a small unit that is scaling quickly from a low base.
- New launches: fresh oncology and chronic therapy approvals from the global pipeline.
- Chronic demand: rising diabetes, heart and cancer cases in India.
- Clean balance sheet: low debt and steady cash, relevant to any AstraZeneca Pharma India share price target 2027 view.
Key Risks in the AstraZeneca Pharma India Analyst Review 2027
- High valuation: about 86 times earnings against an industry P/E near 51.
- Thin margins: operating margin near 13% keeps profit growth behind sales growth.
- Price controls: government pricing rules can cap returns on key drugs.
- Parent dependence: transfer pricing and portfolio choices are set by the group.
- Low free float: only about 25% is held outside the promoter, a key point in the AstraZeneca Pharma India analyst review 2027.
Compare AstraZeneca Pharma India With Other Pharma Stocks on the Univest Screener
AstraZeneca Pharma India Analyst Review 2027: Stock at a Glance
| Metric | Value |
|---|---|
| Share Price (19 Nov 2026) | ₹6,113 |
| 52-Week High / Low | ₹9,264 / ₹5,640 |
| Market Capitalisation | About ₹15,300 crore |
| P/E (TTM) | About 86 |
| Industry P/E | About 51.5 |
| Return on Equity | About 20.2% |
| Debt to Equity | 0.11 |
| Dividend Yield | About 0.6% |
The P/E of about 86 sits well above the industry level, even after a 34% fall from the high. In this AstraZeneca Pharma India analyst review 2027, the premium reflects the parent brand, patented products and fast sales growth, but it leaves little room for a profit miss.
Shareholding Trend
| Holder | Sep 2025 | Sep 2026 | Change |
|---|---|---|---|
| Promoters | 75.00% | 75.00% | No change |
| Foreign Investors (FII) | 2.74% | 2.64% | Down 0.10 pts |
| Domestic Institutions (DII) | 5.26% | 7.09% | Up 1.83 pts |
| Public | 17.00% | 15.27% | Down 1.73 pts |
AstraZeneca Pharmaceuticals AB holds the full 75% promoter stake, the maximum allowed for a listed company. Domestic institutions raised their holding over the year, which the AstraZeneca Pharma India analyst review 2027 reads as rising local fund interest despite the price fall.
What to Watch After the AstraZeneca Pharma India Analyst Review 2027
- Margins: whether operating margin climbs above 13% as sales grow.
- Rare disease sales: how much of the ₹204 crore quarterly run rate holds.
- Launch pipeline: new approvals in oncology and chronic care.
- Leadership: Atul Tandon took over as Chief Financial Officer on 9 November 2026.
- Coverage: any named research that sets an AstraZeneca Pharma India share price target 2027.
Final Word on the AstraZeneca Pharma India Analyst Review 2027
The AstraZeneca Pharma India analyst review 2027 shows a company growing sales about 30% a year with a low-debt balance sheet and strong parent backing. Profit is growing more slowly than revenue, and the stock still trades at a large premium to the sector.
The AstraZeneca Pharma India stock outlook 2027 depends on margin expansion and the pace of new launches. Univest does not give a buy or sell call.
Disclaimer: This article is for educational and informational purposes only and is not investment advice or a recommendation to buy, sell or hold any security. Brokerage ratings and target prices quoted here are opinions of third-party research houses; Univest does not endorse them and gives no buy or sell call. Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.
Frequently Asked Questions
What does the AstraZeneca Pharma India analyst review 2027 show?
It shows fast sales growth with slower profit growth. Q2 FY27 revenue rose 30.4% to ₹729.10 crore, while net profit increased 15% to ₹62.33 crore. Profit before exceptional items and tax rose 32% to ₹103.45 crore.
Is there an AstraZeneca Pharma India share price target 2027 from brokerages?
We could not verify any named brokerage target after the Q2 FY27 results. The stock closed at ₹6,113 on 19 November 2026, about 34% below its 52-week high of ₹9,264. Reported results and valuation are the main reference points for now.
Why did AstraZeneca Pharma India revenue grow so fast?
Growth came from key therapy areas such as oncology and chronic care, plus a sharp rise in rare disease sales. Industry reports said rare disease revenue reached about ₹204 crore in Q2 against about ₹38 crore a year earlier. Q1 FY27 revenue had also grown about 30%.
Why is profit growing slower than revenue for AstraZeneca Pharma India?
The operating margin stayed close to 13% in Q2 FY27. Imported product costs, marketing and staff spending rose along with sales. Net profit therefore grew about 15% while revenue grew about 30%.
Is AstraZeneca Pharma India stock overvalued based on the AstraZeneca Pharma India analyst review 2027?
The stock trades at about 86 times trailing earnings, above the industry P/E of about 51.5. Return on equity is about 20% and debt is low. The premium depends on profit catching up with sales growth.
Who owns AstraZeneca Pharma India?
AstraZeneca Pharmaceuticals AB holds 75% as promoter. Domestic institutions held 7.09% in September 2026, up from 5.26% a year earlier. Foreign investors held 2.64% and the public 15.27%.
What should investors watch after the AstraZeneca Pharma India analyst review 2027?
Watch whether operating margin improves above 13% and whether rare disease sales hold near ₹204 crore a quarter. Track new product approvals and the work of the new CFO. Any named brokerage coverage would also add a fresh reference point.